Novartic has signed a choice agreement with icono, which aims to introduce ophthalmology drug research and development programs

, a private biopharmaceutical company, announced an ophthalmology drug development option agreement with Novartis, according to U.S. business news. Financial details of the deal have not been disclosed.
The role of the option agreement is to help the proposed introducer gain a more comprehensive and in-depth understanding of the proprietary technologies for product development in order to make decisions about the introduction of the technology while protecting the interests of the owner of the know-how. Upon completion of the agreement, Novartic may acquire Icon-4, an ophthalmology drug that Iconic is in the development phase of. Novarccer has made an advance payment and will invest equity in Icon.
ICON-4 is an anti-human tissue factor monoclonal antibody, mainly used to treat age-like macular degeneration (AMD). Iconic plans to begin clinical trials of the drug in 2020.
Founded in 2002 and headquartered in Georgia, Iconic is a clinical biotech and pharmaceutical company. The company develops innovative therapies based primarily on tissue factor (TF) biology to provide treatment options for patients with cancer and severe retinal disease. Tissue factors are trans-membrane single-stranded glycoproteins made up of amino acid residues, which play a key role in inflammation and pathological angiogenesty. Iconic has implemented safely targeted tissue factor technology to treat related diseases.
Iconic's new recombination protein, hI-con1, is licensed exclusively by Yale University. hI-con1 can be combined with tissue factors to activate natural killer cells and selectively destroy pathological new blood vessels. In addition, hI-con1 blocks the positive feedback cycle chain between tissue factors and vascular endosthort growth factors (VEGF), thereby reducing VEGF levels.
Founded in 1996 and headquartered in Basel, Switzerland, Novart is a leading healthcare company in the world. The company's strategic goal is to break the medical paradigm, build a data science-driven, advanced treatment platform, and intervene early in chronic diseases to improve the quality of life of patients. Novarma is sparking a digital revolution, hoping to improve product development efficiency through artificial intelligence and digital technology, and drive innovation in the pharmaceutical industry.
Novaral has tens of thousands of employees and exports drugs to 155 countries around the world. The company's innovative pharmaceutical division, which includes Novarce Pharmaceuticals and Novarce Oncology, is responsible for the development and commercialization of patented drugs. In addition, Novarma, which owns Sandoz, a generics division, is a leader in the biosimilar industry, providing high-quality drugs to a wide range of patients.
Dr William Greene, ceo of Iconic, said: "Targeted tissue factors are new treatments for retinal diseases and cancer, and we are looking for new ways to achieve this technology. Existing AMD therapies, while improving patients' vision, do not prevent the disease from worsening. We believe that suppressing overexpression of macular degeneration-related tissue factors will help improve the efficacy of AMD patients and prevent disease from worsening. " (Arterial mesh)